Status:
UNKNOWN
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Antiplatelet Therapy
CYP2C19 Polymorphism
Eligibility:
All Genders
18+ years
Brief Summary
Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatmen...
Detailed Description
Patients undergoing PCI who received dual antiplatelet therapy with both aspirin (100mg) and P2Y12 inhibitors in standard dosage were enrolled. Investigators examined plasma biomarkers for platelet ac...
Eligibility Criteria
Inclusion
- The patients undergoing PCI
- More than 18 years old
- Treated with aspirin and P2Y12 inhibitors (clopidogrel or ticagrelor)
Exclusion
- Inability to provide written informed consent
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
12000 Patients enrolled
Trial Details
Trial ID
NCT03758248
Start Date
December 1 2018
End Date
September 30 2021
Last Update
December 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029